Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic Tumors

Fudan University

Status: Not yet enrolling

Conditions: Malignant Tumor With Metastasis; CUP

Study type: Observational

Funder types: Other

Identifiers

NCT07319949

SRTCD-NO001

Details and patient eligibility

About

This study will enroll patients with metastatic malignancies. Tumor samples (fresh or formalin-fixed paraffin-embedded tissue specimens) will undergo RNA extraction and next-generation sequencing (RNA-seq). Once the raw data is obtained, the system will analyze the transcriptomic feature values (cancer-specific RNA transcripts and tissue-specific RNA transcripts) expressed in the tumor tissue samples to further predict tissue origin using a machine learning model. The output includes probabilities and confidence intervals for tissue origin.

Full description

This is a non-interventional, observational study. Through a single-center, prospective clinical trial, the study aims to utilize the transcriptomic profiling for tumor tissue origin identification to predict the tissue origin of primary sites in metastatic tumors and evaluate the accuracy and specificity of this prediction solution.

Primary Endpoint:

The accuracy of the transcriptomic profiling for tumor tissue origin identification in predicting the primary site of metastatic tumors (expressed as overall accuracy with its 95% confidence interval).

Secondary Endpoints:

1. The specificity and sensitivity of the transcriptomic profiling for tumor tissue origin identification in predicting the primary site of metastatic tumors.
2. Exploratory analysis of characteristic molecular markers expressed in metastatic lesions from different primary sites.

Enrollment: 30 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Clinically confirmed diagnosis of malignant tumor with metastasis;
2. Metastatic lesions confirmed as malignant by histopathology;
3. Sufficient surgical resection or biopsy specimens retained to meet the requirements for next-generation sequencing;
4. The participant (or their legal representative/guardian) has signed the informed consent form, confirming full understanding of the study's purpose and procedures, and voluntarily agrees to participate.

Exclusion Criteria:

1. The investigator deems the patient unable to provide informed consent.